A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Mivavotinib (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 04 Jun 2024 Results (n=49) assessing safety and efficacy of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 Feb 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2021 Status changed from recruiting to active, no longer recruiting.